140 related articles for article (PubMed ID: 26706174)
21. Insights of tankyrases: A novel target for drug discovery.
Damale MG; Pathan SK; Shinde DB; Patil RH; Arote RB; Sangshetti JN
Eur J Med Chem; 2020 Dec; 207():112712. PubMed ID: 32877803
[TBL] [Abstract][Full Text] [Related]
22. Development of novel dual binders as potent, selective, and orally bioavailable tankyrase inhibitors.
Hua Z; Bregman H; Buchanan JL; Chakka N; Guzman-Perez A; Gunaydin H; Huang X; Gu Y; Berry V; Liu J; Teffera Y; Huang L; Egge B; Emkey R; Mullady EL; Schneider S; Andrews PS; Acquaviva L; Dovey J; Mishra A; Newcomb J; Saffran D; Serafino R; Strathdee CA; Turci SM; Stanton M; Wilson C; Dimauro EF
J Med Chem; 2013 Dec; 56(24):10003-15. PubMed ID: 24294969
[TBL] [Abstract][Full Text] [Related]
23. The Anti-Tumor Activity of Succinyl Macrolactin A Is Mediated through the β-Catenin Destruction Complex via the Suppression of Tankyrase and PI3K/Akt.
Regmi SC; Park SY; Kim SJ; Banskota S; Shah S; Kim DH; Kim JA
PLoS One; 2015; 10(11):e0141753. PubMed ID: 26544726
[TBL] [Abstract][Full Text] [Related]
24. Highly Potent and Isoform Selective Dual Site Binding Tankyrase/Wnt Signaling Inhibitors That Increase Cellular Glucose Uptake and Have Antiproliferative Activity.
Nathubhai A; Haikarainen T; Koivunen J; Murthy S; Koumanov F; Lloyd MD; Holman GD; Pihlajaniemi T; Tosh D; Lehtiö L; Threadgill MD
J Med Chem; 2017 Jan; 60(2):814-820. PubMed ID: 27983846
[TBL] [Abstract][Full Text] [Related]
25. Tankyrase Inhibitors Stimulate the Ability of Tankyrases to Bind Axin and Drive Assembly of β-Catenin Degradation-Competent Axin Puncta.
Martino-Echarri E; Brocardo MG; Mills KM; Henderson BR
PLoS One; 2016; 11(3):e0150484. PubMed ID: 26930278
[TBL] [Abstract][Full Text] [Related]
26. Zoning in on Tankyrases: A Brief Review on the Past, Present and Prospective Studies.
Peters XQ; Malinga TH; Agoni C; Olotu FA; Soliman MES
Anticancer Agents Med Chem; 2019; 19(16):1920-1934. PubMed ID: 31648650
[TBL] [Abstract][Full Text] [Related]
27. Discovery of Novel Spiroindoline Derivatives as Selective Tankyrase Inhibitors.
Shirai F; Tsumura T; Yashiroda Y; Yuki H; Niwa H; Sato S; Chikada T; Koda Y; Washizuka K; Yoshimoto N; Abe M; Onuki T; Mazaki Y; Hirama C; Fukami T; Watanabe H; Honma T; Umehara T; Shirouzu M; Okue M; Kano Y; Watanabe T; Kitamura K; Shitara E; Muramatsu Y; Yoshida H; Mizutani A; Seimiya H; Yoshida M; Koyama H
J Med Chem; 2019 Apr; 62(7):3407-3427. PubMed ID: 30883102
[TBL] [Abstract][Full Text] [Related]
28. Optimization of a Screening Hit toward M2912, an Oral Tankyrase Inhibitor with Antitumor Activity in Colorectal Cancer Models.
Buchstaller HP; Anlauf U; Dorsch D; Kögler S; Kuhn D; Lehmann M; Leuthner B; Lodholz S; Musil D; Radtki D; Rettig C; Ritzert C; Rohdich F; Schneider R; Wegener A; Weigt S; Wilkinson K; Esdar C
J Med Chem; 2021 Jul; 64(14):10371-10392. PubMed ID: 34255518
[TBL] [Abstract][Full Text] [Related]
29. Targeting Wnt-driven cancers: Discovery of novel tankyrase inhibitors.
Ferri M; Liscio P; Carotti A; Asciutti S; Sardella R; Macchiarulo A; Camaioni E
Eur J Med Chem; 2017 Dec; 142():506-522. PubMed ID: 29107427
[TBL] [Abstract][Full Text] [Related]
30. Evaluation and Structural Basis for the Inhibition of Tankyrases by PARP Inhibitors.
Haikarainen T; Narwal M; Joensuu P; Lehtiö L
ACS Med Chem Lett; 2014 Jan; 5(1):18-22. PubMed ID: 24900770
[TBL] [Abstract][Full Text] [Related]
31. Discovery of novel, induced-pocket binding oxazolidinones as potent, selective, and orally bioavailable tankyrase inhibitors.
Bregman H; Chakka N; Guzman-Perez A; Gunaydin H; Gu Y; Huang X; Berry V; Liu J; Teffera Y; Huang L; Egge B; Mullady EL; Schneider S; Andrews PS; Mishra A; Newcomb J; Serafino R; Strathdee CA; Turci SM; Wilson C; DiMauro EF
J Med Chem; 2013 Jun; 56(11):4320-42. PubMed ID: 23701517
[TBL] [Abstract][Full Text] [Related]
32. Preclinical Lead Optimization of a 1,2,4-Triazole Based Tankyrase Inhibitor.
Waaler J; Leenders RGG; Sowa ST; Alam Brinch S; Lycke M; Nieczypor P; Aertssen S; Murthy S; Galera-Prat A; Damen E; Wegert A; Nazaré M; Lehtiö L; Krauss S
J Med Chem; 2020 Jul; 63(13):6834-6846. PubMed ID: 32511917
[TBL] [Abstract][Full Text] [Related]
33. Disruption of Wnt/β-Catenin Signaling and Telomeric Shortening Are Inextricable Consequences of Tankyrase Inhibition in Human Cells.
Kulak O; Chen H; Holohan B; Wu X; He H; Borek D; Otwinowski Z; Yamaguchi K; Garofalo LA; Ma Z; Wright W; Chen C; Shay JW; Zhang X; Lum L
Mol Cell Biol; 2015 Jul; 35(14):2425-35. PubMed ID: 25939383
[TBL] [Abstract][Full Text] [Related]
34. Tankyrase inhibitors as antitumor agents: a patent update (2013 - 2020).
Mehta CC; Bhatt HG
Expert Opin Ther Pat; 2021 Jul; 31(7):645-661. PubMed ID: 33567917
[TBL] [Abstract][Full Text] [Related]
35. Structure-activity relationships of 2-arylquinazolin-4-ones as highly selective and potent inhibitors of the tankyrases.
Nathubhai A; Haikarainen T; Hayward PC; Muñoz-Descalzo S; Thompson AS; Lloyd MD; Lehtiö L; Threadgill MD
Eur J Med Chem; 2016 Aug; 118():316-27. PubMed ID: 27163581
[TBL] [Abstract][Full Text] [Related]
36. Tankyrase Inhibition Causes Reversible Intestinal Toxicity in Mice with a Therapeutic Index < 1.
Zhong Y; Katavolos P; Nguyen T; Lau T; Boggs J; Sambrone A; Kan D; Merchant M; Harstad E; Diaz D; Costa M; Schutten M
Toxicol Pathol; 2016 Feb; 44(2):267-78. PubMed ID: 26692561
[TBL] [Abstract][Full Text] [Related]
37. Tankyrase inhibition impairs directional migration and invasion of lung cancer cells by affecting microtubule dynamics and polarity signals.
Lupo B; Vialard J; Sassi F; Angibaud P; Puliafito A; Pupo E; Lanzetti L; Comoglio PM; Bertotti A; Trusolino L
BMC Biol; 2016 Jan; 14():5. PubMed ID: 26787475
[TBL] [Abstract][Full Text] [Related]
38. Structural basis and SAR for G007-LK, a lead stage 1,2,4-triazole based specific tankyrase 1/2 inhibitor.
Voronkov A; Holsworth DD; Waaler J; Wilson SR; Ekblad B; Perdreau-Dahl H; Dinh H; Drewes G; Hopf C; Morth JP; Krauss S
J Med Chem; 2013 Apr; 56(7):3012-23. PubMed ID: 23473363
[TBL] [Abstract][Full Text] [Related]
39. Zinc binding catalytic domain of human tankyrase 1.
Lehtiö L; Collins R; van den Berg S; Johansson A; Dahlgren LG; Hammarström M; Helleday T; Holmberg-Schiavone L; Karlberg T; Weigelt J
J Mol Biol; 2008 May; 379(1):136-45. PubMed ID: 18436240
[TBL] [Abstract][Full Text] [Related]
40. Recent advances in the structure-based rational design of TNKSIs.
Zhan P; Song Y; Itoh Y; Suzuki T; Liu X
Mol Biosyst; 2014 Nov; 10(11):2783-99. PubMed ID: 25211064
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
